|
UW17114
|
A Phase 1 Dose Escalation, Open-Label Study of Venetoclax in Combination with Navitoclax and Chemotherapy in Subjects with Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma
|
Open |
|
UW13096
|
A Phase 1B, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma |
Open |
|
UW17064
|
A Phase 2, Multi-center, Open Label Study of NIR-178 in Combination with PDR001 in Patients with Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma
|
Open |
|
UW17086
|
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ubilituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma
|
Open |
|
PRE0404
|
A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma |
Open |
|
UW16057
|
A Pilot Randomized Control Trial of a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplant |
Open |
|
ANHL12P1
|
A Randomized Phase II Trial of Brentuximab Vedotin or Crizotinib in combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) (IND#117117) |
Open |
|
EA4151
|
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Cell Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission |
Open |
|
UW17120
|
An Observational Study Profiling Biospecimens from Cancer Patients to Screen for Molecular Alterations (STRATA)
|
Open |
|
UW16086
|
Bendamustine + obinutuzumab induction chemoimmunotherapy with risk-adapted obinutuzumab maintenance therapy in previously untreated mantle cell lymphoma |
Open |
|
UW17038
|
Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial) |
Open |
|
OS11366
|
FAS Apoptotic Pathway Abnormalities in Cutaneous T-Cell Lymphomas
|
Open (affiliates only) |
|
UW15106
|
Genomic analysis of long-term survivors with metastatic cancer |
Open |
|
UW17096
|
Improving Survivorship Care Planning for Bone Marrow Transplant Survivors: A Sociotechnical Systems Approach
|
Open |
|
EAY131
|
Molecular Analysis for Therapy Choice (MATCH) |
Open |
|
APEC1621B
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Tumors Harboring FGFR1/2/3/4 Alterations |
Open |
|
APEC1621F
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations |
Open |
|
APEC1621G
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Braf V600 Mutations |
Open |
|
APEC1621D
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors |
Open |
|
UW16059
|
Patient-related Barriers to Pain Management: Revisiting the Pain Barriers Questionnaire |
Open |
|
HO11414
|
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab + Lenalidomide in Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma |
Open |
|
PRE0403
|
Phase II Study of Venetoclax (ABT-199/GDC-0199) in Combination with Obinutuzumab and Bendamustine in Patient with High Tumor Burden Follicular Lymphoma
|
Open |
|
UW16004
|
Phase Ib Trial of Pembrolizumab in Combination with Dinaciclib in Subject with hematologic Malignancies |
Open |
|
UW17147
|
Pre-Visit Planning in Palliative Care |
Open |
|
S1608
|
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma |
Open |
|
UW13056
|
Women's Integrative Sexual Health (WISH) Program Research Database |
Open |
UW Carbone
